The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 03, 2018

Filed:

Jul. 04, 2014
Applicants:

Vib Vzw, Ghent, BE;

Universiteit Gent, Ghent, BE;

Centre National DE LA Recherche Scientifique, Paris, FR;

Universite Montpellier 2, Montpellier, FR;

Centre Hospitalier Regional Universitaire DE Montpellier, Montpellier, FR;

Inventors:

Jan Tavernier, Balegem, BE;

Sarah Gerlo, Ghent, BE;

Frank Peelman, Gentbrugge, BE;

Gilles Uze, Montpellier, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/00 (2006.01); C07K 14/00 (2006.01); A61K 38/00 (2006.01); C07K 16/40 (2006.01); C07K 14/545 (2006.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/40 (2013.01); C07K 14/545 (2013.01); C07K 16/2869 (2013.01); C07K 16/32 (2013.01); A61K 2039/505 (2013.01); C07K 2317/22 (2013.01); C07K 2317/569 (2013.01); C07K 2319/00 (2013.01);
Abstract

The present disclosure relates to a modified Interleukin-1 (IL-1) family member cytokine, with reduced activity via its cytokine receptor, wherein said interleukin-1 family member cytokine is specifically delivered to target cells. Preferably, the IL-1 family member cytokine is a mutant, more preferably it is a mutant IL-1 with low affinity to the IL-1 receptor, wherein said mutant IL-1 is specifically delivered to target cells. The targeting is preferably realized by fusion of the modified IL-1 family member cytokine to a targeting moiety, preferably an antibody or antibody-like molecule. The disclosure relates further to the use of such targeted modified IL-1 family member cytokine to treat diseases.


Find Patent Forward Citations

Loading…